Press Releases

Date Title and Summary Additional Formats
Toggle Summary AMICUS THERAPEUTICS ANNOUNCES RETURN OF JOHN F. CROWLEY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
AMICUS THERAPEUTICS ANNOUNCES RETURN OF JOHN F. CROWLEY AS PRESIDENT AND CHIEF EXECUTIVE OFFICER Cranbury, NJ, March 5, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human
View HTML
Toggle Summary AMICUS THERAPEUTICS RECEIVES GRANT FROM MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
AMICUS THERAPEUTICS RECEIVES GRANT FROM MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH Cranbury, NJ, January 23, 2007 – Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases,
View HTML
Toggle Summary AMICUS THERAPEUTICS COMMENCES PHASE 1 CLINICAL TRIALS FOR AT2220 FOR POMPE DISEASE
AMICUS THERAPEUTICS COMMENCES PHASE 1 CLINICAL TRIALS FOR AT2220 FOR POMPE DISEASE Cranbury, NJ, DECEMBER 14, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today
View HTML
Toggle Summary AMICUS THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER
AMICUS THERAPEUTICS APPOINTS CHIEF FINANCIAL OFFICER Cranbury, NJ, October 2, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally administered pharmacological chaperones for the treatment of a range of human genetic diseases, today announced the
View HTML
Toggle Summary STUDIES PUBLISHED IN PNAS ON THE MECHANISM OF AMICUS' EXPERIMENTAL TREATMENT FOR GAUCHER DISEASE
STUDIES PUBLISHED IN PNAS ON THE MECHANISM OF AMICUS' EXPERIMENTAL TREATMENT FOR GAUCHER DISEASE Cranbury, NJ, September 20, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human
View HTML
Toggle Summary AMICUS THERAPEUTICS RAISES $60 MILLION SERIES D FINANCING
Company Also Makes Two Key Executive Appointments
View HTML
Toggle Summary AMICUS THERAPEUTICS ADDS GLENN P. SBLENDORIO TO BOARD OF DIRECTORS
Company Makes Executive and Management Appointments
View HTML
Toggle Summary AMICUS THERAPEUTICS FILES FOR INITIAL PUBLIC OFFERING
AMICUS THERAPEUTICS FILES FOR INITIAL PUBLIC OFFERING Cranbury, NJ, May 17, 2006 - Amicus Therapeutics, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock.
View HTML
Toggle Summary AMICUS THERAPEUTICS FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR AT2101 FOR GAUCHER DISEASE
Phase I Clinical Trials Expected to Commence in June
View HTML
Toggle Summary AMICUS THERAPEUTICS FILES INVESTIGATIONAL NEW DRUG APPLICATION FOR AT2101 FOR GAUCHER DISEASE
Phase I Clinical Trials Expected to Commence in June
View HTML